Acorda Therapeutics Inc

Acorda Therapeutics — Q3 2022 Earnings Presentation

25 slides from Acorda Therapeutics's earnings presentation, Nov 1, 2022

  1. Slide 1: Acorda Therapeutics Q3 Earnings Call

    Acorda Therapeutics Q3 Earnings Call November 1, 2022

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Forward-Looking Statements This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are

  3. Slide 3: Agenda

    Agenda Q3 highlights INBRIJA AMPYRA Long-term business plan Financials and guidance Special meeting of stockholders 3 2022 Q3 EARNINGS

  4. Slide 4: INBRIJA Net U.S. Sales - Q3 2022

    INBRIJA Net U.S. Sales - Q3 2022 $7.85M Q3 2022 net sales 1% increase vs Q3 2021 104% increase vs Q1 2022 4 2022 Q3 EARNINGS

  5. Slide 5: INBRIJA U.S. Trends - 2022

    INBRIJA U.S. Trends - 2022 $M Net Sales TRX Cartons 9 3300 3249 10500 7.85 8 7.6 3200 10000 9924 7 3100 9500 6 2995 9087 3000 5 9000 2900 4 3.7 8500 8305 2800 2761 3 8000 2 2700 2600 7500 1 0 2500 7000 Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3 -26% 16% 1% -12% -14% -8% -5% -5% -1% Change from same quarter 2021 5 2

  6. Slide 6: INBRIJA Ex-U.S. Sales

    INBRIJA Ex-U.S. Sales INBRIJA ex-U.S. – Germany launch June 2022 • Early launch stock of $960k in Q3, following $1.9M in Q2 – Spain launch expected early 2023 – Biopas working toward launches in 9 largest LatAm markets – Ongoing discussions for additional territories in EU and Asia 6 2022 Q3 EARNING

  7. Slide 7: AMPYRA Net U.S. Sales - Q3 2022

    AMPYRA Net U.S. Sales - Q3 2022 $21.1M Q3 2022 net sales 5% increase vs Q3 2021 7 2022 Q3 EARNINGS

  8. Slide 8: Maintaining Branded AMPYRA

    Maintaining Branded AMPYRA $50MM $44.2MM $45MM $40.6MM $40.8MM $40MM $37.6MM $35MM $30MM $27.2MM $25.8MM $25.3MM $25MM $21.8MM $22.5MM $20.3MM $21.1MM $19.9MM $20.0MM $20MM $18.2MM $14.9MM $15MM $10MM $5MM $0MM Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2019 2019 2019 2019 2020 2020 2020 2020 2021

  9. Slide 9: AMPYRA Ex-U.S. Revenue

    AMPYRA Ex-U.S. Revenue FAMPYRA royalties of $2.6M – Double-digit, tiered royalties Launch in China 9 2022 Q3 EARNINGS

  10. Slide 10: Long-Term Business Plan

    Long-Term Business Plan 10 2022 Q3 EARNINGS

  11. Slide 11: Long-Term Business Plan Overview

    Long-Term Business Plan Overview INBRIJA will continue to grow in the U.S. INBRIJA will expand into additional ex-U.S. markets AMPYRA will continue to lose market share, but at a stabilizing rate Capitalized to execute plan – Expect to be cash-flow positive in 2023 Shareholder approval of reverse st

  12. Slide 12: Broadening the Use of On-Demand Treatments in PD

    Broadening the Use of On-Demand Treatments in PD 2022 ODT Prescription Volume Market Share1 INBRIJA currently enjoys a 67% market share within the on-demand treatment class1 33% Healthcare professionals report they are generally more comfortable with INBRIJA than apomorphine-based on-demand treatmen

  13. Slide 13: INBRIJA Commercial Activities

    INBRIJA Commercial Activities • Launching new brand campaign in November • Emphasizing the emotional impact of OFF periods on everyday activities for patients and care partners • Educating on the importance of on-demand treatments • Three new peer reviewed publications • Increasing investment in dig

  14. Slide 14: Increasing Acceptance of Need for On-Demand Treatments

    Increasing Acceptance of Need for On-Demand Treatments 14 2022 Q3 EARNINGS

  15. Slide 15: INBRIJA Before & After Videos

    INBRIJA Before & After Videos Jimmy Rachel 15 2022 Q3 EARNINGS

  16. Slide 16: Maintaining Branded AMPYRA

    Maintaining Branded AMPYRA AMPYRA currently holds ~15% of dalfampridine market1 AMPYRA net sales currently at ~13% of 2017 sales – Long-term value of the brand expected at ~10% of 2017 sales through 2027 Field team continues to promote the brand – ~200 HCPs resumed prescribing of AMPYRA in 2022 Phys

  17. Slide 17: Financials and Guidance

    Financials and Guidance 17 2022 Q3 EARNINGS

  18. Slide 18: Q3 2022 Financial Summary

    Q3 2022 Financial Summary ∆ YTD YTD ∆ ($ in millions) 3Q’22 3Q’21 Q/Q 2022 2021 Y/Y Net WW INBRIJA Revenue 8.9 7.8 14.1% 21.8 19.2 13.5% Net AMPYRA Revenue 21.1 20.0 5.5% 54.2 62.1 (12.7%) R&D 1.4 1.9 (26.3%) 4.6 9.1 (49.5%) SG&A 23.0 29.6 (22.3%) 80.0 96.0 (16.7%) GAAP Net Loss (13.9) (27.1) (48.7%

  19. Slide 19: AMPYRA Arbitration Award

    AMPYRA Arbitration Award Alkermes Arbitration – $16.5M award to Acorda • $15.0M award • $1.5M pre-judgment interest – Acorda will no longer pay royalties on net sales for license and supply of AMPYRA – Freedom to use alternate sources of supply • Sources have been secured – $10-$12M savings in 2023

  20. Slide 20: Financial Guidance

    Financial Guidance ($ in millions) 2022 2023 2024 2025 2026 2027 Net Revenue INBRIJA U.S. $27.8 - $28.7 $37.1 - $41.1 $50.1 - $55.3 $59.7 -$65.9 $64.1 - $70.9 $71.4 - $78.9 Inbrija Ex-U.S. $2.8 - $2.9 $7.3 - $8.1 $12.0 - $13.2 $22.7 - $25.1 $33.1 - $36.6 $45.0 - $49.7 Inbrija Sales $30.6 - $31.6 $44

  21. Slide 21: Building Long Term Value

    Building Long Term Value Accelerate INBRIJA growth Optimize Financial Structure • PWP returning to more active lives • OpEx discipline • Re-engage physicians • Fampyra royalties revert in 2022 post-pandemic • Inbrija ex-US revenue • Commercialize ex-U.S. Maintain AMPYRA Strength Leverage ARCUS platf

  22. Slide 22: Special Meeting of Stockholders 2022

    Special Meeting of Stockholders 2022 22 2022 Q3 EARNINGS

  23. Slide 23: November 4, 2022 Special Meeting of Stockholders – Two Proposals

    November 4, 2022 Special Meeting of Stockholders – Two Proposals1 Reverse split – Required to ensure ACOR is not delisted from Nasdaq in December – Delisting could result in default to bondholders – Value of shareholders position in ACOR will not change Adjournment if needed to obtain more votes All

  24. Slide 24: How to Vote

    How to Vote Please vote via one of the methods below as soon as possible to ensure that your vote is counted: BY INTERNET Visit www.proxyvote.com until 11/03/22 BY MAIL Sign, date and return your proxy card in the postage-paid stamped envelope provided BY PHONE Call 1-800-690-6903 by 11/03/22 BY SMA

  25. Slide 25: LIFE.

    LIFE. SCIENCE. °

Acorda Therapeutics — Q3 2022 Earnings Presentation on 6ix